Omnicell Inc (OMCL) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Product Revenue: $182 million, up $24 million from the previous quarter and $37 million from Q4 2023.
Service Revenue: $125 million, an increase of $1 million over the previous quarter and $11 million over Q4 2023.
Non-GAAP Gross Margin: 47.4%, an increase of 290 basis points from the prior quarter.
GAAP Earnings Per Share (EPS): $0.34, compared to $0.19 in the prior quarter and a loss of $0.32 in Q4 2023.
Non-GAAP EPS: $0.60, compared to $0.56 in the prior quarter and $0.33 in the same period last year.
Non-GAAP EBITDA: $46 million, an increase of $8 million from the previous quarter and $23 million from the same period last year.
Cash and Cash Equivalents: $369 million, down from $571 million as of September 30, 2024.
Non-GAAP Free Cash Flow: $43 million for Q4 2024.
Inventory: $89 million as of December 31, 2024, a decrease of $6 million from the prior quarter.
Bookings for Full Year 2024: $923 million, exceeding guidance of $800 million to $875 million.
Total Backlog: $1.201 billion as of December 31, 2024.
Full Year 2024 Revenue: $1.112 billion, a decrease of $35 million or 3% from 2023.
Full Year 2024 Non-GAAP EPS: $1.71, a decrease of $0.20 from 2023.
Full Year 2024 Non-GAAP EBITDA: $136 million.
Warning! GuruFocus has detected 5 Warning Signs with OMCL.
Release Date: February 06, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Omnicell Inc (NASDAQ:OMCL) exceeded its bookings guidance for 2024, driven by strong demand for connected devices.
The company returned to year-over-year revenue growth in Q4 2024, with total revenues reaching $307 million.
Omnicell Inc (NASDAQ:OMCL) solidified its balance sheet by issuing new convertible senior notes and repurchasing a majority of the principal amount of previously outstanding notes.
The XT Amplify program continues to gain traction, with significant customer wins and market share gains.
Annual recurring revenue (ARR) is expected to grow, contributing significantly to overall revenue, with specialty pharmacy services as a key driver.
Despite strong bookings, Omnicell Inc (NASDAQ:OMCL) anticipates product bookings to be flat to modestly down in 2025 compared to 2024.
The company faces a $0.20 headwind to non-GAAP earnings per share in 2025 due to reduced interest income from repurchasing convertible senior notes.
Cash and cash equivalents decreased significantly from $571 million to $369 million by the end of Q4 2024.
Omnicell Inc (NASDAQ:OMCL) is concluding the XT replacement cycle, which may impact future bookings and revenue growth.
The company is navigating potential tariff risks and cost of goods challenges, although it has strategies in place to mitigate these impacts.
Q: Can you expand on the end market demand and how it translates into budget growth? A: Randall Lipps, CEO, explained that hospital financial conditions have improved, contributing to strong bookings in the fourth quarter. This positions Omnicell well for 2025, with expectations for continued growth into 2026. The improved financial position of customers makes decision-making easier, and the excitement around the XT Amplify program facilitates investment now rather than later.
Q: How should we think about the trajectory of gross margin and operating expense growth in 2025? A: Nchacha Etta, CFO, noted that gross margins improved in 2024 and are expected to continue improving in 2025. This will be driven by managing expenses, favorable product and customer mix, and operational improvements. The focus remains on improving overall profitability through fiscal discipline.
Q: What contributed to the upside in bookings in 2024? A: Nchacha Etta, CFO, highlighted significant demand for connected devices and additional bookings from XT upgrades, including market share gains. The XTExtend program also contributed to improved bookings performance.
Q: How does the new administration's focus on technology innovation impact Omnicell's business? A: Randall Lipps, CEO, stated that the administration's focus on efficiency and safety aligns with Omnicell's core strengths. The company is well-positioned to leverage its innovation in making customers more efficient and safe, which should drive better returns and outcomes.
Q: What is the outlook for the XT Amplify and XTExtend pipelines? A: Nchacha Etta, CFO, mentioned that the adoption of XT Amplify and XTExtend follows a traditional bell curve. Hospitals are moving back into capital equipment markets, which could accelerate adoption. The company is optimistic about continuing momentum into 2025 and beyond.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Apple Is Going To Surprise Wall Street, Says Tom Lee, As iPhone Maker 'Could Be Quietly Ready To Pounce On AI'
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. As Wall Street has been rallying behind the iPhone maker, led by Tim Cook, to dive into the artificial intelligence (AI) race, Fundstrat's Tom Lee says that Apple Inc. (NASDAQ:AAPL) could be ready to surprise investors. Check out the current price of AAPL stock here. What Happened: While a slew of opinions on Apple's acquisition of Perplexity AI make rounds on mainstream media and among top Wall Street experts, Lee's post on X highlights his belief in Apple's enduring strength and strategic timing in the market. He suggests that Apple is poised to make significant moves that could surprise investors. Trending: Tired of Grid Failures and Charging Deserts? This Startup Has a Solar Fix and $25M+ in Sales — In a snippet of his conversation with CNBC, reshared on X, Lee says, "For me, Apple has been quietly ready to pounce on AI. But I don't think they need to pay up for any of these models. So, I think Apple is going to surprise people."While Lee doesn't specifically vouch for Apple's acquisition of Perplexity AI, he seems confident that Cook to make a strategic move into AI. Meanwhile, Lee's peers Daniel Ives of Wedbush Securities and Jim Cramer have been urging the iPhone maker to acquire Peplexity. According to Bloomberg Opinion's U.S. technology columnist Dav Lee, Apple should continue its measured approach to building AI capabilities by hiring individual talent, rather than acquiring entire AI companies. He highlights that large acquisitions might seem tempting to quickly enhance Siri and other AI tools, but it carries significant risks of cultural clashes, operational hurdles, and regulatory It Matters: Cramer, in a recent X post had reiterated his views that "If Apple buys Perplexity, we would have our winning bot and the stock would soar." Cramer also calls out Apple on its buyback program and said that "Continued buybacks will do nothing." This comes as Apple spent the most on stock buybacks in recommendation is influenced by the U.S. government's antitrust ruling against Alphabet Inc.'s (NASDAQ:GOOG) (NASDAQ:GOOGL), expected by August, which may force Google to end default search deals with Apple's Safari browser. Similarly, Ives said at the beginning of July that Apple's 'treadmill approach' needs to end, and it needs to eye a big, splashing partnership with either Perplexity or Anthropic. 'Look, it's about the developers. If you look at OpenAI, if you look at Google, if you look at Microsoft, they (Apple) need to get into the game. That is something that can't be done in Cupertino,' he added. Read Next: Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs — And You Can Invest At Just $6.37/Share If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Image via Shutterstock This article Apple Is Going To Surprise Wall Street, Says Tom Lee, As iPhone Maker 'Could Be Quietly Ready To Pounce On AI' originally appeared on
Yahoo
27 minutes ago
- Yahoo
MicroStrategy (MSTR) Stock Slides as Market Rises: Facts to Know Before You Trade
In the latest close session, MicroStrategy (MSTR) was down 3.22% at $412.67. The stock's performance was behind the S&P 500's daily gain of 0.78%. Elsewhere, the Dow saw an upswing of 1.14%, while the tech-heavy Nasdaq appreciated by 0.61%. Coming into today, shares of the business software company had gained 13.1% in the past month. In that same time, the Computer and Technology sector gained 8.76%, while the S&P 500 gained 5.88%. Investors will be eagerly watching for the performance of MicroStrategy in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on July 31, 2025. It is anticipated that the company will report an EPS of -$0.12, marking a 84.21% rise compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $112.15 million, indicating a 0.64% growth compared to the corresponding quarter of the prior year. For the full year, the Zacks Consensus Estimates are projecting earnings of -$15.73 per share and revenue of $466.5 million, which would represent changes of -134.08% and +0.66%, respectively, from the prior year. Additionally, investors should keep an eye on any recent revisions to analyst forecasts for MicroStrategy. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability. Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. MicroStrategy presently features a Zacks Rank of #3 (Hold). Investors should also note MicroStrategy's current valuation metrics, including its Forward P/E ratio of 58.41. This expresses a premium compared to the average Forward P/E of 24.84 of its industry. The Computer - Software industry is part of the Computer and Technology sector. At present, this industry carries a Zacks Industry Rank of 39, placing it within the top 16% of over 250 industries. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report MicroStrategy Incorporated (MSTR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
40 minutes ago
- Yahoo
Nutex Health Responds to Short Seller Report
HOUSTON, July 23, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in 11 states and primary care-centric, risk-bearing physician networks, today provided the following response to a misleading short attack. The Company is aware of the allegations made in a recent short seller report that attempts to call into question the Company's collection process. As previously disclosed, Nutex Health has developed a robust internal process to code, bill and, if necessary after a federally mandated negotiation period, submit eligible medical claims to independent dispute resolution. The Company strongly disagrees with the allegations in the report and believes it is without merit. Further, the Company believes the report contains misrepresentations and conveys a misunderstanding of Nutex Health's business. Nutex Health expects to provide related updates in its upcoming earnings release and Form 10-Q for the second quarter of 2025 due on or before August 14, 2025. About Nutex Health Inc. Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. (NASDAQ: NUTX) is a healthcare management and operations company with two divisions: a Hospital Division and a Population Health Management Division. The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 24 facilities in 11 states. The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organization (MSO), we provide management, administrative and other support services to our affiliated hospitals and physician groups. Forward-Looking Statements Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases "will", "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," "goal," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act , economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company's ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Annual Report on Form 10-K for the year ended December 31, 2024, under the heading "Risk Factors" in Part II, Item IA thereof, and the risk factors and other cautionary statements contained in our other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. View original content: SOURCE Nutex Health, Inc. Sign in to access your portfolio
